Romanow: Cap payer drug costs

Putting a $1,500 limit on drug costs, and having the government pick up the rest of the tab, could have a significant positive impact on employer-sponsored plans
By David Brown
|Canadian HR Reporter|Last Updated: 09/04/2003

It's not clear what, if anything, will become of the Romanow and Kirby reports on health care, but there is some reason for employers to be hopeful about proposed changes, say workplace benefit experts.

Both the Romanow Commission and the Kirby report call for changes that could have a significant positive impact on employer-sponsored drug costs — one of the fastest growing burdens for private health-plan sponsors. Both reports identified rising drug costs as a problem and propose the government cover the cost for prescriptions beyond a certain point.

The Standing Senate Committee on Social Affairs, Science and Technology chaired by Senator Michael Kirby released its report,